1 / 7

Characteristics and Outcomes of Patients in the GISSI-HF Study: A Detailed Analysis

This study, published in The Lancet, presents a comprehensive analysis of the baseline characteristics of patients enrolled in the GISSI-HF trial. It details time to all-cause death and hospitalization for cardiovascular reasons using Kaplan-Meier curves. Additionally, it explores secondary outcomes, causes of death, and provides a predefined subgroup analysis of composite endpoints. The findings also address permanent treatment discontinuations and adverse drug reactions, shedding light on the efficacy and safety of treatment options for heart failure patients.

trevor-mccray
Télécharger la présentation

Characteristics and Outcomes of Patients in the GISSI-HF Study: A Detailed Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  2. Baseline characteristics of patients GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  3. Kaplan-Meier curves for time to all-cause death (A) and for time to all-cause death or admission to hospital for cardiovascular reasons (B) GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  4. Secondary outcomes GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  5. Causes of death GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  6. Predefined subgroup analysis-composite endpoint of all-cause death or admission to hospital for cardiovascular reasons GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

  7. Permanent treatment discontinuations and adverse drug reactions GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

More Related